- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02663427
Serological Screening of Gastric Cancer in Wuxi Region
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gastric cancer is the third largest cause of cancer related deaths in China with about 350 ,000 gastric cancer-related deaths by gastric cancer in 2012. The studies from Japan and Korea have found gastric cancer screening, especially of the mass population, reduces mortality from gastric cancer, but the data is seldom in China. The ways include radiographic and endoscopic screening, although those methods were shown to reduce gastric cancer mortality, and was recommended as gold standard for population-based screening by Japan and Korea, but many problems have been pointed out: A serious drawback is low uptake of the target population; fear for radiation exposure(0.6 mSv), swallowing unpleasantness due to the use of barium meal, accidental fall during the examination and constipation, causing rare but more serious complications such as intestinal obstruction or diverticulitis after examination may account for the reasons for this low uptake, endoscopic screening is labor-intensive, more costly per examination as complete disinfection of the scope is mandatory, and requires a large number of well-trained experienced endoscopists.
Serological method, so-called ABC method , has been useful as gastric cancer preliminary screening in some areas, such as China, Japan and Korea. The major reasons are attributed to its simplicity, safety (radiation-free, discomfort free), and cost-efficiency. The ABC method is a blood test to stratify the risk of gastric cancer using the combination of H. pylori antibody and pepsinogen I and II, that was documented by large-scale studies in Japan. But the data was short in China, especially in the community.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Age 40-70 years old, men and women are not limited, and there are one of the following:
- Hp infected.
- Previously suffering from chronic atrophic gastritis, gastric ulcer, gastric polyps, hypertrophic gastritis, pernicious anemia and other precancerous diseases of the stomach.
- First degree relatives of patients with gastric cancer.
- Other risk factors for gastric cancer. (high salt, salted diet, smoking, heavy drinking, etc.)
Exclusion Criteria:
- Severe heart, liver, kidney, dysfunction or mental disorders
- History of gastric surgery (including surgery, minimally invasive EMR, ESD)
- Use of PPI, acid preparation, stomach protecting agent in the first two weeks
- The researchers considered inappropriate participants.
- Informed consent cannot be attained
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PG(-) and Hp(-) Group
PG negative (pepsinogen(PG)Ⅰ > 70ng/ml or PGⅠ/PGⅡ >7.0)and Hp (helicobacter pylori) negative.
A questionnaire survey are accomplished in 40-70 years old candidates.
Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination.
Gastroscope also accomplished in all participants.
|
|
Experimental: PG(-) and Hp(+) Group
PG negative and Hp positive.
A questionnaire survey are accomplished in 40-70 years old candidates.
Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination.
Gastroscope also accomplished in all participants.
|
|
Experimental: PG(+) and Hp(-) Group
PG positive (PGⅠ ≤ 70ng/ml and PGⅠ/PGⅡ≤7.0)
and Hp negative.
A questionnaire survey are accomplished in 40-70 years old candidates.
Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination.
Gastroscope also accomplished in all participants.
|
|
Experimental: PG(+) and Hp(+) Group
PG positive and Hp positive.
A questionnaire survey are accomplished in 40-70 years old candidates.
Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination.
Gastroscope also accomplished in all participants.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
detection rate of gastric cancer among all group
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Z201501
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stomach Neoplasms
-
Jeeyun LeeRecruitingStomach Cancer, AdenocarcinomaKorea, Republic of
-
Chinese University of Hong KongUnknown
-
Chinese University of Hong KongUnknown
-
National Cancer Center, KoreaUnknownSubmucosal Tumor of StomachKorea, Republic of
-
Xijing Hospital of Digestive DiseasesCompletedStomach Cancer | Esophageal Cancer | Esophageal Dysplasia | Stomach DysplasiaChina
-
Chinese University of Hong KongRecruiting
-
Universitätsklinikum Hamburg-EppendorfOvesco Endoscopy AGSuspendedSubmucosal Tumor of StomachGermany
-
Soonchunhyang University HospitalCompletedMalignant Neoplasm of Stomach | Benign Neoplasm of StomachKorea, Republic of
-
Fujian Cancer HospitalCompletedMalignant Neoplasm of Stomach Stage IVChina
-
Federation Francophone de Cancerologie DigestiveEli Lilly and CompanyActive, not recruitingStomach Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Stomach NeoplasmFrance
Clinical Trials on serological examination and gastroscope
-
GCS Ramsay Santé pour l'Enseignement et la RechercheNot yet recruiting
-
Institute of Tropical Medicine, BelgiumInstitut National de Recherche Biomédicale. Kinshasa, République Démocratique... and other collaboratorsCompletedCovid19Congo, The Democratic Republic of the
-
Universitair Ziekenhuis BrusselRecruiting
-
Universitair Ziekenhuis BrusselActive, not recruiting
-
Universitair Ziekenhuis BrusselRecruiting
-
National Taiwan University HospitalRecruiting
-
Istituto Auxologico ItalianoFederico II University; ASST Fatebenefratelli SaccoRecruitingResistance, Thyroid HormoneItaly
-
Indonesia UniversityUniversitas Sumatera Utara; Eijkman Institute for Molecular Biology; Eijkman... and other collaboratorsActive, not recruiting
-
University of MilanUnknown
-
Central Hospital, Nancy, FranceCompletedSmoking BehaviorsFrance